Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Investing.com - Mizuho has upgraded uniQure BV (NASDAQ:QURE) from Neutral to Outperform and raised its price target to $30.00 from $20.00, citing the potential of the company’s Huntington’s disease therapy. The stock has shown strong momentum, gaining over 117% in the past year, according to InvestingPro data.
The upgrade reflects Mizuho’s belief that uniQure’s AMT-130 could become a dominant treatment in the Huntington’s disease landscape, potentially reaching a broader patient population than previously estimated. While the company currently operates with moderate debt levels, InvestingPro data shows its liquid assets exceed short-term obligations with a current ratio of 9.98.
Mizuho has increased its market penetration forecast from 5% to 12% of total disease prevalence, projecting 2035 peak unadjusted sales of $2.5 billion and adjusted sales of $1.8 billion for the therapy.
The firm noted that uniQure’s current stock price does not appear to account for likely positive three-year data from the Phase 1/2 trial expected in late September 2025, which could support a Biologics License Application filing for accelerated approval in the first quarter of 2026.
Mizuho also highlighted that AMT-130 may avoid the fatal acute liver failure risks associated with some AAV-based gene therapies due to its direct administration into the brain, lower viral load, and prophylactic immunosuppression protocol.
In other recent news, uniQure N.V. reported its second-quarter financial results, revealing a revenue of $5.3 million, which fell short of analyst expectations of $5.4 million. This figure also represents a significant drop from the $11.1 million reported in the same period last year. The decline in revenue was largely attributed to a $7.1 million decrease in collaboration revenue and a $2.1 million reduction in contract manufacturing of HEMGENIX for CSL Behring. Despite the revenue shortfall, uniQure posted a loss of $0.69 per share, which was narrower than the anticipated loss of $0.89 per share as projected by analysts. These recent developments have been closely watched by investors, particularly in light of the ongoing cash burn and the company’s progress in its clinical pipeline. Analyst firms have not yet provided any upgrades or downgrades in response to these earnings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.